First Patient Dosed in Trial of [212Pb]VMT01 for Metastatic Melanoma
Source: CureToday, April 2025
The first patient has been dosed with [212Pb]VMT01 in a phase 1/2a trial evaluating the safety of the agent in patients with melanoma.
The first patient has been dosed with [212Pb]VMT01 — a targeted alpha-particle therapy — in a phase 1/2a trial evaluating the safety of the agent in patients with histologically confirmed melanoma and positive melanocortin 1 receptor (MC1R) imaging scans, according to a news release from Perspective, Therapeutics, Inc.
In this cohort of patients, researchers are evaluating the investigative drug at 1.5 mCi in combination with the PD-1 blocking antibody Opdivo (nivolumab), whereas in earlier cohorts, patients received [212Pb]VMT01 as a monotherapy. The news release goes on to state that initial results from earlier cohorts of treatment with the monotherapy were presented in October of 2024 at the 21st International Congress of the Society for Melanoma Research.